Greystone Research Associates is pleased to announce the publication of a new
market study. Product Strategies for Non-Oral Hematology Drugs is a
comprehensive analysis of the technology, products and participants that
comprise this segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug
developers, formulation specialists, device designers, healthcare marketers,
and supply chain participants with a detailed understanding of the products,
markets and strategic opportunities for non-oral hematology drugs. Provider
organization business managers, healthcare administrators and investors will
also benefit from this study.
The Evolving Landscape for Therapeutic Hematology Drugs
The administration of non-oral drugs for the treatment of blood disorders has
evolved over the past ten years to include heparin analogs and recombinant
proteins designed to treat chronic conditions that are life threatening and
often debilitating illnesses. As the availability of drugs based on new APIs
or molecular entities has grown, the product strategies in the marketplace
have increased in specificity and sophistication. The chronic nature of many
blood diseases and the growing trend toward patient self-administration for
non-oral medications is requiring drug developers and product managers to
refine their product strategy at the highest level, with formulation and
device selection decisions being made prior to the clinical trial phase of
development.
The result has been greater reliance on concurrent product development
processes and stronger partnerships between drug companies and device
designers. Formulations that can extend the half-life of hematology drugs are
also gaining traction, as developers strive to create drugs with lower dosing
frequencies as a way to improve patient safety and compliance. These factors
are combining to make hematology drug product strategies more complex and
multi-faceted, and challenging managers to think and react well beyond
traditional drug development models.
About Greystone Research
Greystone Associates is a medical technology consulting firm focused on the
areas of medical market strategy, product commercialization, venture
development, and market research. We assist medical and healthcare market
participants in achieving their business objectives through the creation of
detailed development strategies, product commercialization programs, and
comprehensive market and technology research and analysis.
Our market research publications are designed, researched and written to
provide timely and insightful information and data on focused market segments,
with the aim of providing market participants with the essential knowledge to
refine and execute their marketing plans and financial targets.
Table of Contents
Table of Contents
Executive Summary
Therapeutic Hematology Market Dynamics
Evolution in Drug Therapies
Growth of Self-Administration
Key Markets for Hematology Drug Therapeutics
Anemia
Deep Vein Thrombosis
Heart Valve Prosthesis
Neutropenia
Pulmonary Embolism
Competitive Landscape
Opportunities and Risks
Non-Oral Hematology Drug Formulation and Packaging Factors
Extended Release Formulations
Packaging - Vial vs Prefilled Device
Vial Strategies
Prefilled Device Strategies
Prefilled Syringes
Autoinjectors
Pen Injectors
Non-Oral Hematology Drug Administration Factors
Dosing
Dose Frequency
Route of Administration
Intravenous
Subcutaneous
Non-Oral Hematology Drugs - Product Analysis and Market Data
Anticoagulants
Heparin
Enoxaparin
Lovenox
Unbranded Enoxaparin
Fondaparinux
Arixtra
Unbranded Fondaparinux
Fragmin
Hematopoietics and Related Erythropoiesis Stimulating Proteins
Darbepoetin alfa
Epoetin alfa
Epoetin beta
Epogen
Filgrastim
Pegfilgrastim
Profiles of Hematology Drug Companies
Product Strategies for Non-Oral Hematology Drugs published by Greystone Research Associates in June 4, 2012. This report price starts from US $ 2850.
